A recent survey by the Kaiser Family Foundation (KFF) revealed that approximately 12% of U.S. adults have used GLP-1 medications such as Ozempic, Wegovy, or Mounjaro for conditions like diabetes, heart disease, or weight loss. The prevalence of GLP-1 medication usage is notably higher among individuals with diabetes at 43%, followed by those with heart disease at 26%, and individuals who are obese or overweight at 22%.
About 12% of all Americans have taken Ozempic or another GLP-1 drug, according to a new survey released Friday by health policy research nonprofit KFF. https://t.co/oWyUH7KCh1
1 in 8 adults say they've taken a GLP-1 weight-loss drug. https://t.co/5m1ovZRjLr
⚠️ ROUGHLY 1 IN 8 US ADULTS HAVE TAKEN GLP-1 DRUGS LIKE WEGOVY, POLL SHOWS Full Story → https://t.co/9JdCH0SqOq About one in eight adults have taken a drug belonging to the GLP-1 class of medications for weight loss and related conditions, a poll by Kaiser Family Foundation…
about one in eight adults (12%) say they have ever taken a GLP-1 agonist like Ozempic or Wegovy. https://t.co/FsJdHZofPW
WOW: One in 8 adults has used Ozempic or similar GLP-1 weight-loss drugs https://t.co/Pe9ZXnDrmg
The shares of adults who report ever taking a GLP-1 medication is highest among people with diabetes (43%), followed by those with heart disease (26%) and those who have obesity or are overweight (22%). See more findings in our report: https://t.co/SQ6smpzrQj https://t.co/du2kGtIaGn
About 1 in 8 adults (12%) say they have taken a GLP-1 medication — like Ozempic, Wegovy or Mounjaro — to treat a chronic condition, such as diabetes or heart disease, or to lose weight. Learn more from our latest Health Tracking Poll: https://t.co/SQ6smpzrQj